Should I buy Medtronic (MDT) stock or is it too late?
⭐ The most reliable of them, either direction: Bernstein — 67% of its targets hit on this sector (64 calls tested). It aims for $97 (+7.8 %), call made on June 6, 2026, maturing on June 6, 2027 (83 d ago).
Firm-by-firm track record on Medtronic
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| JP Morgan | 100 % | +16.0 % | 7 | $100 +11% |
| BTIG | 86 % | +15.7 % | 7 | $91 +1% |
| Barclays | 78 % | +12.6 % | 9 | $120 +33% |
| Citigroup | 68 % | +9.0 % | 25 | $110 +22% |
| UBS | 45 % | +5.7 % | 11 | $100 +11% |
| Evercore ISI Group | 80 % | +4.3 % | 5 | $105 +17% |
| Mizuho | 57 % | +4.3 % | 7 | $100 +11% |
| Needham | 50 % | -2.5 % | 8 | $101 +12% |
✅ Reasons to believe
- 76% of analysts rate it a buy (Buy consensus, 17 ratings) — a sign of market conviction.
- Median price target $100, i.e. +11% from the current price ($90).
- The most reliable firm on MDT, JP Morgan (100% hit rate, 7 scored calls), targets $100 (call made on February 18, 2026, maturing on February 18, 2027) (+11%) in its most recent call, and $100 (call made on November 13, 2025, maturing on November 13, 2026) (+11%) in the one coming due soonest.
- 7 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.
- Pays a dividend (3.6% yield), raised for 22 years — regular income on top of potential upside.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 17 ratings, 4 are neutral.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
The analyst consensus on MDT
Median target $100 (+11%) · 17 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Medtronic now?
We won't decide for you. The facts: 76% of analysts rate it a buy, median target $100 (+11%), and JP Morgan (most reliable on MDT, 100%) targets $100. Weigh that against valuation (P/E ~24). This is not personalized advice.
Is it too late to invest in Medtronic?
Not according to analysts: the median target ($100) is still +11% above the current price ($90) (most reliable on MDT: JP Morgan, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Medtronic still worth investing in?
It depends on the gap between the price ($90) and its estimated value: analysts target $100 on median (+11%), with 76% buys (most reliable on MDT: JP Morgan, 100%). Cross-check with their real reliability on MDT and the cautions above. Information, not advice.
What's the main risk in buying MDT?
The consensus is not unanimous: of 17 ratings, 4 are neutral.
→ Go deeper: the full Medtronic profile (consensus, analyst reliability, price target, performance).